)
Visual
test
Microba Life Sciences
Microba Life Sciences (MAP) investor relations material
Microba Life Sciences Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary29 Jan, 2026
Executive summary
Core clinical testing volumes grew 90% year-on-year, with an annualized run rate exceeding 21,300 tests and on track to surpass 24,000 for regional break-even in Australia and the UK by FY26.
Microbiome Explorer now represents 55% of total revenue, reflecting a full transition from legacy products, which are now fully discontinued.
UK market adoption is 33% higher than Australia at the equivalent post-launch period, leveraging an acquired customer base and enhanced product features.
AI-driven transformation has delivered significant operational efficiencies, with over 70% of customer inquiries resolved autonomously and a 94.7% satisfaction score.
Major brand consolidation and new product features, such as the Oral Species Biomarker and Pay on Invoice, have improved operational efficiency and clinical utility.
Financial highlights
Core testing revenue rose 123% year-on-year, with Q2 FY26 total revenue at $3.72m and FY25 revenue at $15.67m.
Over $1.6 million in legacy product revenue replaced by core products, with legacy product roll-off now complete.
UK Invivo-branded supplements delivered a record quarter, with PHGG prebiotic supplement volumes up 110% year-on-year.
Net operating cash outflows reduced to $1.6m in Q2 FY26, reflecting cost reductions and R&D tax incentive receipt.
Cash balance as of 31 Dec 2025 was $11.27 million, with estimated 7 quarters of funding at current burn rate.
Outlook and guidance
On track for regional break-even in Australia and the UK by FY26, targeting over 24,000 core tests for the full year.
Group EBITDA break-even expected with further scale and continued strong clinical adoption.
Expansion into the US and Europe planned, contingent on regulatory pathways and successful laboratory partnerships.
Expect continued acceleration in clinical adoption and revenue growth as legacy product wind-down is complete.
Cash receipts expected to normalize from Q3 FY26 as payment term changes cycle through.
What specific results will unlock therapeutic deals?
How does product-led growth reduce customer acquisition cost?
Detail non-dilutive funding opportunities
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights.
Microba Life Sciences
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Microba Life Sciences Limited is a biotechnology company specializing in microbiome analysis and therapeutics. The company provides advanced gut microbiome testing services using metagenomic sequencing technology to offer insights into human health. Microba also conducts research and development to discover and develop microbiome-based therapeutics targeting conditions such as inflammatory and metabolic diseases. The company is headquartered in Brisbane, Australia, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage